[Effect of prodigiozan on the antibody-dependent cytotoxicity of neutrophils in chronic myeloid leukemia]. 1989

S A Guseva, and L M Tishchenko

Decreased levels of neutrophils, Fc- and C3-expressing receptors, oxygen-dependent metabolism as well as antibody-dependent cytotoxicity of these cells to target cells were identified in advanced chronic myeloid leukemia, particularly, in blast crisis. Treatment with cytostatic agents resulted in further decrease in said parameters. However, treatment with prodigiozan was followed by improvement in cell functioning.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D011135 Polysaccharides, Bacterial Polysaccharides found in bacteria and in capsules thereof. Bacterial Polysaccharides
D011354 Prodigiozan A polysaccharide extracted from Serratia marcescens and other bacteria. It activates enzymatic activity of macrophages and stimulates phagocytic processes. Prodigiosan
D011951 Receptors, Complement Molecules on the surface of some B-lymphocytes and macrophages, that recognize and combine with the C3b, C3d, C1q, and C4b components of complement. Complement Receptors,Complement Receptor,Complement Receptor Type 1,Receptor, Complement
D011961 Receptors, Fc Molecules found on the surface of some, but not all, B-lymphocytes, T-lymphocytes, and macrophages, which recognize and combine with the Fc (crystallizable) portion of immunoglobulin molecules. Fc Receptors,Fc Receptor,Receptor, Fc
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females

Related Publications

S A Guseva, and L M Tishchenko
January 1993, Comparative immunology, microbiology and infectious diseases,
S A Guseva, and L M Tishchenko
June 1995, Immunology and cell biology,
S A Guseva, and L M Tishchenko
January 1982, Advances in experimental medicine and biology,
S A Guseva, and L M Tishchenko
January 2013, American journal of nephrology,
Copied contents to your clipboard!